Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.71 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.71 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863883 | 1.00 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL4129145 | 0.91 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL4705732 | 0.90 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL1042379 | 0.88 | TLR7 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL4125001 | 0.88 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL18204188 | 0.88 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL22341400 | 0.87 | TLR7 (0.55) | TLR7TLR8NUDT1 | |
| SCHEMBL23255722 | 0.87 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| Hydrochloric Acid SCHEMBL4134550 | 0.87 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL2744557 | 0.87 | TLR7 (0.68) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | claimed |
| EP-3763742-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-10-05 | — | — | EP | claimed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| EP-4001311-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2022-05-25 | — | — | EP | claimed |
| US-20260049145-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2026-02-19 | — | — | US | disclosed |
| EP-4691562-A2 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2026-02-11 | — | — | EP | disclosed |
| EP-4001311-B1 | ANTI-PD-L1/PD-1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2025-11-05 | — | — | EP | disclosed |
| US-20250122304-A1 | PRE-TARGETING | PRECIRIX N.V. (BE) | 2025-04-17 | — | — | US | disclosed |
| CN-119584994-A | Pre-targeting | 普雷西里克斯公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| WO-2023213801-A1 | PRE-TARGETING | PRECIRIX N.V. (BE) | 2023-11-09 | — | — | WO | disclosed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-06-09 | — | — | US | disclosed |
| EP-4001311-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2022-05-25 | — | — | EP | disclosed |
| US-20220089749-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-03-24 | — | — | US | disclosed |
| US-11279761-B2 | Anti-PD-L1 combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-03-22 | — | — | US | disclosed |
| WO-2022053651-A2 | ANTIBODY FRAGMENT AGAINST FAP | PRECIRIX N.V. (BE) | 2022-03-17 | — | — | WO | disclosed |
| EP-3166976-B1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-02-23 | — | — | EP | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049145-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | TLR7 57/4885TLR8 90/4885NUDT1 4361/4885 |
| US-11279761-B2 | Anti-PD-L1 combinations for treating tumors | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885TLR8 585/4885NUDT1 3947/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 883/4885TLR8 671/4885NUDT1 4325/4885 |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | IFNG, CD47, CD74 | TLR7 75/4885TLR8 61/4885NUDT1 3300/4885 |
| US-20250122304-A1 | PRE-TARGETING | HNRNPH1, NR1H4, HNRNPH3 | TLR7 2062/4885TLR8 3196/4885NUDT1 2674/4885 |
| US-20220089749-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885NUDT1 3504/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.